Video
Dr. Leventakos on Remaining Questions After PACIFIC Trial in Lung Cancer
Author(s):
Konstantinos Leventakos, MD, discusses the impact of the PACIFIC trial on the stage III non–small cell lung cancer treatment, as well as what questions still remain.
Konstantinos Leventakos, MD, assistant professor of oncology, Mayo Clinic, discusses the impact of the PACIFIC trial on the stage III non—small cell lung cancer (NSCLC) treatment, as well as what questions still remain.
The PACIFIC trial showed the addition of durvalumab (Imfinzi) as consolidation therapy significantly improved progression- free survival and overall survival versus placebo in patients with stage III NSCLC who did not have disease progression after 2 or more cycles of platinum-based chemoradiation. Now, more patients with stage III NSCLC should be eligible for immunotherapy, according to Leventakos.
Remaining questions include whether immunotherapy can be administered earlier in patients with stage III NSCLC, and if so, the optimal duration of the treatment. Leventakos believes these questions will soon be answered through clinical trials.
